SMMT Rasio cepet Summit Therapeutics

Summit Therapeutics is integrating ESG principles into the development of anti-infectives by reducing harmful laboratory emissions. The ratio of cash and accounts receivable to short-term debt demonstrates current solvency, with the latest value recorded as 6.62. However, a high dependency on a single drug and research expenditures create risks. The asset's capitalization is currently determined solely by the success of clinical trials in oncology.

Quick liquidity determines a company's ability to settle short-term debts without liquidating inventory. The calculation is based on the sum of cash and accounts receivable, excluding low-liquidity assets. Analyzing this solvency ratio, net of inventory, reveals the real capital cushion. For Summit Therapeutics (SMMT), this is critically important when financing costly global trials of ivonescimab to capture the oncology market.